AAAAAA

   
Results: 1-12 |
Results: 12
Metachronous gonadal and extragonadal primacies, or late relapse of germ cell tumor?
Authors: Daniel, C Fizazi, K Culine, S Zelek, L Wibault, P Theodore, C
Citation: C. Daniel et al., Metachronous gonadal and extragonadal primacies, or late relapse of germ cell tumor?, UROL ONCOL, 6(2), 2001, pp. 49-52
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
Authors: Zelek, L Barthier, S Riofrio, M Sevin, D Fizazi, K Spielmann, M
Citation: L. Zelek et al., Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes, ANN ONCOL, 12(9), 2001, pp. 1265-1268
Gastric metastases from breast cancer - A retrospective series of 12 patients
Authors: Zelek, L Cottu, PH Mignot, L de Roquancourt, A Fizazi, K Cojean-Zelek, I Espie, M Marty, M
Citation: L. Zelek et al., Gastric metastases from breast cancer - A retrospective series of 12 patients, AM J CL ONC, 24(4), 2001, pp. 363-365
Chemotherapy of nonoperable colorectal liver metastases
Authors: Piedbois, P Zelek, L Cherqui, D
Citation: P. Piedbois et al., Chemotherapy of nonoperable colorectal liver metastases, HEP-GASTRO, 48(39), 2001, pp. 711-714
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
Authors: Zelek, L Barthier, S Riofrio, M Fizazi, K Rixe, O Delord, JP Le Cesne, A Spielmann, M
Citation: L. Zelek et al., Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, CANCER, 92(9), 2001, pp. 2267-2272
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers
Authors: Ahomadegbe, JC Tourpin, S Kaghad, M Zelek, L Vayssade, M Mathieu, MC Rochard, F Spielmann, M Tursz, T Caput, D Riou, G Benard, J
Citation: Jc. Ahomadegbe et al., Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers, ONCOGENE, 19(47), 2000, pp. 5413-5418
Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms
Authors: Fizazi, K Zelek, L
Citation: K. Fizazi et L. Zelek, Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms, ANN ONCOL, 11(2), 2000, pp. 133-149
High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients
Authors: Cottu, PH Zelek, L Extra, JM Espie, M Mignot, L Morvan, F Marty, M
Citation: Ph. Cottu et al., High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients, ANN ONCOL, 10(7), 1999, pp. 795-801
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer
Authors: Spielmann, M Llombart, A Zelek, L Sverdlin, R Rixe, O Le Cesne, A
Citation: M. Spielmann et al., Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer, ANN ONCOL, 10(12), 1999, pp. 1457-1460
ErbB-2 and breast cancer: toward a personalization of adjuvant therapy?
Authors: Zelek, L
Citation: L. Zelek, ErbB-2 and breast cancer: toward a personalization of adjuvant therapy?, B CANCER, 85(11), 1998, pp. 922-923
NSABP P-1: the last article!
Authors: Zelek, L
Citation: L. Zelek, NSABP P-1: the last article!, B CANCER, 85(11), 1998, pp. 923-924
The rare cancer bank of the AJOF: Introduction and preliminary results
Authors: Zelek, L Fizazi, K
Citation: L. Zelek et K. Fizazi, The rare cancer bank of the AJOF: Introduction and preliminary results, EUROCANCER 98, 1998, pp. 147-148
Risultati: 1-12 |